BioSpace News Archive

Nuclera, the biotechnology company accelerating protein expression and purification workflows through its benchtop eProtein Discovery™ system, announced it has been awarded two highly competitive Innovate UK grants totaling £1.14M.

BWXT Medical Ltd. has submitted a Drug Master File to the U.S. Drug and Food Administration for No Carrier Added Actinium-225 Active Pharmaceutical Ingredient.

NovaBay® Pharmaceuticals, Inc. announces that the NYSE American LLC has accepted the Company’s plan to regain compliance with NYSE American’s continued listing standards.

Brii Biosciences Limited presented new data from two Phase 2 studies evaluating BRII-179 either as a combination therapy with BRII-835 (elebsiran) or as an add-on therapy to pegylated interferon-alpha (PEG-IFNα) treatment for chronic hepatitis B virus (HBV) infection at the EASL™ (European Association for the Study of the Liver) Congress 2024.

Scinai Immunotherapeutics Ltd. today announced that on June 5, 2024, it received formal notification from the Listing Qualification Department (the “Staff”) of the Nasdaq Stock Market (“Nasdaq”) that the Company has regained compliance with the minimum $1.00 bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) (the “Rule”).

Kura Oncology, Inc. today announced that on June 3, 2024, the Compensation Committee of the Company’s Board of Directors (the “Compensation Committee”) granted inducement awards consisting of nonstatutory stock options to purchase 152,500 shares of common stock to eight (8) new employees.

The 2024 American Society of Clinical Oncology Annual Meeting convened from May 31 to June 4, 2024 in Chicago, USA, adopting a hybrid format.

Boehringer Ingelheim announced breakthrough results from a survodutide Phase II trial sub-analysis that demonstrate up to 64.5% of adults with fibrosis stages F2 and F3 achieved an improvement in fibrosis without worsening of metabolic dysfunction-associated steatohepatitis, versus 25.9% with placebo after 48 weeks of treatment [response difference: 38.6% (95% CI 18.1% - 59.1%), p=0.0005].

Calico Life Sciences LLC today announced that its investigational eIF2B activator fosigotifator (ABBV-CLS-7262) has been accepted into the U.S. Food and Drug Administration (FDA) Support for clinical Trials Advancing Rare disease Therapeutics (START) Pilot Program.

Nusano, Inc., a physics company transforming the production of medical radioisotopes, announced industry veteran D. Scott Holbrook as chairman of its board.